Icecure Medical Ltd Dossier - Source-backed chat

Icecure Medical Ltd

ICCMNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.65

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $1.69Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $7.8M

Enterprise Value −$1M

Shares Outstanding 3.4M diluted

Next Earnings Date18 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

IceCure Medical is transitioning from a clinical-stage developer to a high-growth commercial medtech player following the landmark FDA marketing authorization of its ProSense® Cryoablation System for low-risk breast cancer in women aged 70 and older. The company's liquid-nitrogen-based technology offers a highly satisfying, minimally invasive outpatient alternative to surgical lumpectomy. With an established reimbursement framework, a newly approved post-market study design (ChoICE Trial) to drive clinical adoption, and a recent $5.5 million premium private placement securing near-term runway, IceCure is well-positioned to capture a significant share of the early-stage breast cancer market.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$22.67

High · most bullish analyst$30.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.00

Slower-than-expected physician adoption and clinical enrollment in the ChoICE trial delay commercial momentum. Continued high sales, marketing, and clinical trial expenses exhaust cash reserves faster than anticipated, necessitating further dilutive equity raises. Regulatory delays in Canada and Japan limit geographic expansion.

Base CaseCentral scenario

$1.00

Steady commercial rollout of ProSense® in the U.S. with patient enrollment for the ChoICE post-market study commencing in H2 2026. Revenue grows in line with consensus estimates (~$6.37M in FY 2026 and ~$12.55M in FY 2027), supported by the active commercial install base. Gross margins gradually recover as production scales and high-margin disposable probe sales increase.

Bull CaseUpside scenario

$30.00

Rapid commercial adoption of ProSense® in the U.S. driven by the updated 2026 ASBrS Resource Guide recommending cryoablation. Successful expansion of regulatory approvals in Canada and Japan, combined with a swift ramp-up of the 30 hybrid commercial-clinical sites, accelerates recurring revenue from disposable probes, leading to a faster path to profitability by 2028.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First and only medical device to receive FDA marketing authorization for the local treatment of early-stage, low-risk breast cancer.
Strong clinical validation from the ICE3 trial showing low recurrence rates (3.61%) and high patient satisfaction (95% in THERMAC trial).
High-margin 'razor-and-blade' business model with recurring revenue from proprietary single-use disposable cryoprobes.
Favorable clinical guidelines with the American Society of Breast Surgeons (ASBrS) recommending cryoablation as an option in its updated 2026 Resource Guide.

Key Investment Risks

Commercial execution risk in a highly competitive oncology space dominated by medtech giants with larger sales forces.
Near-term unprofitability and cash burn, requiring careful capital management despite the recent $5.5 million private placement.
Reimbursement hurdles and varying coverage policies across different insurance providers and geographic regions.

Thesis Invalidation Triggers

Failure to initiate or meet enrollment targets for the ChoICE Trial Post-Market Study in H2 2026.
Rejection or significant delays of regulatory applications by Health Canada or Japan's PMDA.
Inability to maintain Nasdaq compliance or severe equity dilution from future capital raises.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.